Pulmonx to Report Third Quarter 2026 Financial Results on October 27, 2026GlobeNewsWire · Oct 13, 2026
Owlet (NYSE:OWLT) and Pulmonx (NASDAQ:LUNG) Financial ReviewDefense World · Oct 5, 2026
Deutsche Bank AG Takes Position in Pulmonx Corporation $LUNGDefense World · Sep 2, 2026
Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Sep 1, 2026
Pulmonx to Participate in Upcoming Investor ConferencesGlobeNewsWire · Aug 27, 2026
Pulmonx Corporation (LUNG) Now Trades Above Golden Cross: Time to Buy?Zacks Investment Research · Aug 26, 2026Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 29, 2026 | -$0.28 | -$0.24 | Beat |
| Apr 29, 2026 | -$0.33 | -$0.33 | Beat |
| Mar 4, 2026 | -$0.39 | -$0.25 | Beat |
| Nov 12, 2025 | -$0.40 | -$0.34 | Beat |
| Jul 30, 2025 | -$0.40 | -$0.38 | Beat |
| Apr 30, 2025 | -$0.37 | -$0.36 | Beat |